We are live on ! Find out more
SONN

Sonnet BioTherapeutics
SONN

Delisted

SONN was delisted on the 2nd of December, 2025.

Back to rankings

1 hedge funds and large institutions have $170K invested in Sonnet BioTherapeutics in 2025 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

10.77% less ownership

Funds ownership: 11.29% → 0.53% (-11%)

95% less capital invested

Capital invested by funds: $3.53M → $170K (-$3.36M)

96% less funds holding

Funds holding: 27 → 1 (-26)

96% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 27

Holders
1
Holders Change
-26
Holders Change %
-96.3%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
27
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FAM
Formidable Asset Management
Ohio
+$168K

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$687K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$441K
3
HF
HRT Financial
New York
-$340K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$283K
5
BFM
Boothbay Fund Management
New York
-$258K
Name Holding Trade Value Shares
Change 		Change in
Stake
FAM
1
Formidable Asset Management
Ohio
$170K +$168K +37,185 New
IC
2
Ikarian Capital
Texas
– -$687K -150,000 Closed
Vanguard Group
3
Vanguard Group
Pennsylvania
– -$441K -96,382 Closed
HF
4
HRT Financial
New York
– -$340K -74,265 Closed
Geode Capital Management
5
Geode Capital Management
Massachusetts
– -$283K -61,840 Closed
BFM
6
Boothbay Fund Management
New York
– -$258K -56,339 Closed
Goldman Sachs
7
Goldman Sachs
New York
– -$253K -55,134 Closed
BC
8
BIT Capital
Germany
– -$221K -48,358 Closed
Citadel Advisors
9
Citadel Advisors
Florida
– -$211K -46,082 Closed
VF
10
Virtu Financial
New York
– -$120K -26,266 Closed
Morgan Stanley
11
Morgan Stanley
New York
– -$118K -25,808 Closed
State Street
12
State Street
Massachusetts
– -$103K -22,534 Closed
BlackRock
13
BlackRock
New York
– -$100K -21,940 Closed
Northern Trust
14
Northern Trust
Illinois
– -$81.8K -17,860 Closed
Bank of America
15
Bank of America
North Carolina
– -$76.9K -16,784 Closed
Two Sigma Investments
16
Two Sigma Investments
New York
– -$68.6K -14,972 Closed
IHL
17
Investment House LLC
California
– -$48.7K -10,625 Closed
Jane Street
18
Jane Street
New York
– -$48.4K -10,562 Closed
JP Morgan Chase
19
JP Morgan Chase
New York
– -$34.5K -7,537 Closed
LFG
20
Larson Financial Group
Missouri
– -$19.7K -4,303 Closed
TRCT
21
Tower Research Capital (TRC)
New York
– -$4.81K -1,051 Closed
SSG
22
Summit Securities Group
New York
– -$4.58K -1,000 Closed
ASN
23
Advisory Services Network
Georgia
– -$2.91K -636 Closed
UBS Group
24
UBS Group
Switzerland
– -$1.27K -277 Closed
GSWM
25
Golden State Wealth Management
California
– -$925 -202 Closed
1
2

SONN Hedge Fund Activity: Q4 2025 in Review

1 of the 8,224 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q4 2025, worth a combined $170K — down 95% from $3.53M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of SONN and 1 opened new positions — a net loss of 26 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was Formidable Asset Management, opening a new position worth an estimated $168K. The largest seller was Ikarian Capital, exiting entirely with an estimated $687K sold.

  • 1 institutional investor held Sonnet BioTherapeutics (SONN) as of Q4 2025, down from 27 in Q3 2025.
  • Funds reported $170K of Sonnet BioTherapeutics stock for Q4 2025, down 95% quarter-over-quarter.
  • 1 fund opened new Sonnet BioTherapeutics positions in Q4 2025 and 27 closed out, a net change of -26 holders.
  • The largest Sonnet BioTherapeutics buyer in Q4 2025 was Formidable Asset Management, an estimated $168K added.
  • The largest Sonnet BioTherapeutics seller in Q4 2025 was Ikarian Capital, an estimated $687K sold.

Based on aggregated 13F filings for Q4 2025.